Open Label Pilot Study of the Effects of Memantine on FDG-PET in Frontotemporal Dementia
Memantine has been approved for use in Alzheimer's disease. Its mechanism of action raises questions of whether it can also be effective for non-Alzheimer's dementias such as frontotemporal dementia (FTD), which currently has no disease-modifying treatment.
This is an open-label study to probe the effects of memantine in 15 outpatients diagnosed with FTD, as shown objectively by comparing PET scans performed before and after use of the medication. The specific type of PET scan, FDG-PET, allows the investigators to gauge the effects of memantine on cortical activity levels. The investigators hypothesize that subjects on memantine will show normalization of cortical metabolic activity.
|Study Design:||Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||An Open Label Pilot Study of the Effects of Memantine Administration on FDG-PET in Frontotemporal Dementia|
- Metabolic activity in frontal and temporal lobes. [ Time Frame: 6 months ] [ Designated as safety issue: No ]
- Behavioural inventories, UPDRS Motor scale. [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
|Study Start Date:||October 2007|
|Study Completion Date:||June 2012|
|Primary Completion Date:||June 2012 (Final data collection date for primary outcome measure)|
Drug: memantine hydrochloride
|Toronto, Ontario, Canada, M6A 2E1|
|Principal Investigator:||Tiffany W Chow, MD||Rotman Research Institute at Baycrest, University of Toronto|